SLV 310

Drug Profile

SLV 310

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Solvay
  • Class Antipsychotics; Phthalimides; Pyridines
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 06 Apr 2004 Solvay and Wyeth Pharmaceuticals formed a worldwide agreement to co-develop and co-commercialise SLV 310
  • 28 Jan 2003 Phase-II clinical trials in Psychotic disorders (unspecified route)
  • 31 Jul 2000 Phase-I clinical trials for Psychotic disorders (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top